Finds that testing for safety and effectiveness of prescrption drugs in Canada takes place almost exclusively before medications are approved and that there are “few regulatory obligations once a product reaches the market.”Assesses the Canadian post-market systems of drug surveillance - “pharmacovigilance” - and finds that there is no national system to test drugs for safety after they reach the market.